KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Leases (2019 - 2026)

Gsk has reported Leases over the past 8 years, most recently at $941.0 million for Q1 2026.

  • For Q1 2026, Leases fell 8.55% year-over-year to $941.0 million; the TTM value through Mar 2026 reached $941.0 million, down 8.55%, while the annual FY2025 figure was $965.7 million, 11.06% down from the prior year.
  • Leases for Q1 2026 was $941.0 million at Gsk, down from $965.7 million in the prior quarter.
  • Over five years, Leases peaked at $1.2 billion in Q4 2023 and troughed at $134.2 million in Q1 2022.
  • A 5-year average of $923.5 million and a median of $965.7 million in 2025 define the central range for Leases.
  • Biggest five-year swings in Leases: tumbled 87.7% in 2022 and later skyrocketed 494.24% in 2023.
  • Year by year, Leases stood at $805.8 million in 2022, then soared by 44.32% to $1.2 billion in 2023, then fell by 6.63% to $1.1 billion in 2024, then decreased by 11.06% to $965.7 million in 2025, then dropped by 2.55% to $941.0 million in 2026.
  • Business Quant data shows Leases for GSK at $941.0 million in Q1 2026, $965.7 million in Q4 2025, and $1.1 billion in Q3 2025.